After the German government recommended its administration to people aged 18 to 64 years of age only, AstraZeneca plc (AZN) defended its vaccine’s effectiveness against the new coronavirus in the elderly.
A spokesman for the British-Swedish group AstraZeneca plc (AZN) explained that the newest analysis “supports this hypothesis” of vaccine effectiveness for those over 65, pending a decision by the European Medicines Agency “which is expected to come on Friday.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Boris Johnson, the British Prime Minister, who expressed approval for the vaccination for the elderly, stressed that the British Authority for Health Products recognized the vaccine to be effective and of “high grade”.
Moreover, AstraZeneca plc (AZN) is ready to release the contract signed with the European Union to deliver vaccines against COVID-19. According to the newspaper Frankfurter Allgemeine, they plan to present the proposals they made to them to the European Commission on Friday.
According to a source in the paper, although AstraZeneca will not deliver the 80 million doses of COVID-19 vaccine, the volumes will be far higher than the previously reported 31 million doses.
AstraZeneca plc (AZN) was recently at the centre of controversy between European government capitals and the pharmaceutical company when it was revealed that the company would not meet its targets for vaccine delivery as promised.
